Royal Bank of Canada Portfolio holdings
Royal Bank of Canada (RBC), founded in 1864 and headquartered in Toronto, is Canada’s largest bank by market capitalization and one of the leading financial institutions in North America, offering a comprehensive suite of services including personal and commercial banking, wealth management, insurance, and capital markets. Managing hundreds of billions in assets, RBC serves millions of clients globally, with a significant presence in the U.S. and Caribbean through subsidiaries like RBC Wealth Management and City National Bank. Known for its stability and consistent profitability, RBC has earned a reputation as a conservative yet innovative bank, expanding its digital offerings and sustainability initiatives in recent years. With a strong focus on customer service and a robust international footprint, RBC remains a cornerstone of the Canadian and global financial systems.
Top Buys
| 1 |
Toronto Dominion Bank
TD
|
+$397M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
+$305M |
| 3 |
Manulife Financial
MFC
|
+$293M |
| 4 |
iShares MSCI EAFE ETF
EFA
|
+$293M |
| 5 |
Bank of Montreal
BMO
|
+$258M |
Top Sells
| 1 |
Alphabet (Google) Class C
GOOG
|
+$310M |
| 2 |
FRC
First Republic Bank
FRC
|
+$204M |
| 3 |
Intel
INTC
|
+$176M |
| 4 |
Willis Towers Watson
WTW
|
+$176M |
| 5 |
GFLU
GFL Environmental Inc. Tangible Equity Units
GFLU
|
+$163M |
Sector Composition
| 1 | Financials | 21.66% |
| 2 | Technology | 14.22% |
| 3 | Communication Services | 8.29% |
| 4 | Healthcare | 8.27% |
| 5 | Consumer Discretionary | 7.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3601
John Hancock Multifactor Developed International ETF
JHMD
$778M
| $635K | ﹤0.01% |
19,013
-3,980
| -17% | -$133K |
|
3602
WisdomTree Europe Quality Dividend Growth Fund
EUDG
$81.1M
| $633K | ﹤0.01% |
19,720
+500
| +3% | +$16.1K |
|
3603
Fate Therapeutics
FATE
$115M
| $633K | ﹤0.01% |
10,670
-139,818
| -93% | -$8.29M |
|
3604
WM Technology
MAPS
$139M
| $633K | ﹤0.01% |
43,676
-15,347
| -26% | -$222K |
|
3605
Oil-Dri
ODC
$1.01B
| $633K | ﹤0.01% |
36,188
+404
| +1% | +$7.07K |
|
|
NVRO
3606
DELISTED
NEVRO CORP.
NVRO
| $633K | ﹤0.01% |
5,440
-16,657
| -75% | -$1.94M |
|
3607
Invesco Global ex-US High Yield Corporate Bond ETF
PGHY
$188M
| $632K | ﹤0.01% |
29,096
+1,109
| +4% | +$24.1K |
|
3608
Pilgrim's Pride
PPC
$9.83B
| $632K | ﹤0.01% |
21,729
-52,704
| -71% | -$1.53M |
|
|
ACTDU
3609
DELISTED
ArcLight Clean Transition Corp. II Unit
ACTDU
| $632K | ﹤0.01% |
63,657
+13,300
| +26% | +$132K |
|
|
DFP
3610
Flaherty & Crumrine Dynamic Preferred and Income Fund
DFP
$450M
| $630K | ﹤0.01% |
21,886
+10,386
| +90% | +$299K |
|
3611
Madrigal Pharmaceuticals
MDGL
$9.82B
| $629K | ﹤0.01% |
7,873
+174
| +2% | +$13.9K |
|
3612
Mine Safety
MSA
$6.68B
| $628K | ﹤0.01% |
4,311
-1,052
| -20% | -$153K |
|
|
BRCN
3613
DELISTED
Burcon NutraScience Corporation
BRCN
| $628K | ﹤0.01% |
402,098
-61,650
| -13% | -$96.3K |
|
3614
Avantis International Small Cap Value ETF
AVDV
$12.2B
| $627K | ﹤0.01% |
9,696
-20,662
| -68% | -$1.34M |
|
3615
Invesco Pharmaceuticals ETF
PJP
$266M
| $627K | ﹤0.01% |
8,105
-1,854
| -19% | -$143K |
|
|
HOOK
3616
DELISTED
HOOKIPA Pharma
HOOK
| $626K | ﹤0.01% |
10,639
+7,053
| +197% | +$415K |
|
|
ECF
3617
Ellsworth Growth & Income Fund
ECF
$159M
| $624K | ﹤0.01% |
46,708
+2,209
| +5% | +$29.5K |
|
3618
iShares MSCI Thailand ETF
THD
$234M
| $624K | ﹤0.01% |
8,362
+3,515
| +73% | +$262K |
|
3619
Codexis
CDXS
$225M
| $623K | ﹤0.01% |
26,781
+1,986
| +8% | +$46.2K |
|
3620
Invesco India ETF
PIN
$214M
| $623K | ﹤0.01% |
21,847
-11,491
| -34% | -$328K |
|
3621
Climb Global Solutions
CLMB
$620M
| $622K | ﹤0.01% |
23,100
+16,900
| +273% | +$455K |
|
3622
Evolent Health
EVH
$1.01B
| $621K | ﹤0.01% |
20,039
+2,134
| +12% | +$66.1K |
|
|
CPARU
3623
DELISTED
Catalyst Partners Acquisition Corp. Unit
CPARU
| $621K | ﹤0.01% |
63,065
+6,692
| +12% | +$65.9K |
|
|
CDK
3624
DELISTED
CDK Global, Inc.
CDK
| $621K | ﹤0.01% |
14,591
-129,291
| -90% | -$5.5M |
|
3625
Arbutus Biopharma
ABUS
$847M
| $620K | ﹤0.01% |
144,437
+85,542
| +145% | +$367K |
|